Adagio Medical Names Todd Usen as CEO & Director

Adagio Medical Holdings, a company focused on catheter ablation tech to treat cardiac arrhythmias, revealed founder Olav Bergheim has departed as CEO and chairperson of the board of directors of the company.

The company appointed Todd Usen as CEO and director and Orly Mishan as chairperson of the board, effective December 13, 2024. Bergheim will stay an advisor to Adagio and support Usen with the transition through December 13, 2025.

“We are grateful to Olav for his dedication and contributions to Adagio. Under his leadership the Company made substantial clinical and operational strides, and is NASDAQ-listed,” said Orly Mishan. “We are extremely fortunate to add Todd, who has a breadth of commercial and operational experience and a proven track record leading large and complex medical device businesses, to the Adagio team. Todd has demonstrated exceptional leadership in building, restructuring, and growing public and private organizations. His efforts have been driven by a strong focus on corporate development, product innovation, logistics and go-to-market strategies.”

Before joining Adagio, Usen was president and CEO of Minerva Surgical, where he successfully restructured the company, completed successful financings, and drove top-line growth. Before that, he was CEO of Activ Surgical, overseeing FDA and CE clearance of advanced surgical imaging technology. His career also includes executive roles at Smith+Nephew and Boston Scientific.

Usen is currently executive chairman of medical robotics company Rob Surgical, chairman of NeoPredics, and director of Alesi Surgical.

“I’m thrilled to join Adagio at this important junction in the Company’s history, supporting initial commercial efforts in Europe, and the FULCRUM-VT trial enrollment in the United States,” said Todd Usen. “With a growing body of evidence demonstrating both the safety and effectiveness of Adagio’s Ultra-Low Temperature Cryoablation technology, and marked enthusiasm of users in both Europe and North America, I believe that Adagio’s VT Cryoablation System with vCLAS catheter will become the future standard of care for treatment of patients with ventricular tachycardia.”

“It has been an honor to lead Adagio over the last 13 years delivering on our mission of improving the quality of life and long-term outcomes in patients with cardiac arrhythmias. I am proud of what we have accomplished together, and I am confident that Adagio is poised for continued success,” said Olav Bergheim.